Merck & Co's experimental blood lump stopper vorapaxar can be a root cause of bleeding in patients who before experienced a knock, investigators concerned in clinical tests of the drug established it on Wednesday.

Merck is revising vorapaxar for the avoidance of cardiac actions and had intended to put forward the anti-clotting drug this year to the Food and Drug Administration for sanction.

Shares of Merck had forced when the drug maker said it close down a study of vorapaxar in stroke sufferers and would discontinue giving the drug. At the time Merck said it was ending the study in patients with sensitive coronary syndrome because that test had reached a programmed number of endpoints, or medical matters like cardiovascular deaths, heart attacks and strokes.

Merck executives had rejected to involve in a discussion call previous week on whether there were bleeding anxiety with the drug or why the trials were stopped and distorted. The drug company said that it made the verdict based on reference from an independent Data and Safety Monitoring Board, or DSMB that reviewed the experiments.

The drug, meant to stop heart attacks and strokes or their recurrence, was measured a top gemstone in Merck's duct.